Introduction
The genus Aglaia comprises over 100 species that occur in moist tropical forests in the IndoMalaysian region (Mabberley et al., 1995) . In re cent years Aglaia species have attracted attention due to their unique l//-cyclopenta(b)benzofuran lignans (also called rocaglamide derivatives) that have been isolated from over 10 Aglaia species so far and are exclusively confined to members of this genus (e.g. Dumontet et al., 1996; Cui et al., 1997; Nugroho et al., 1997a; Nugroho et a l, 1997b; Giissregen et a l, 1997; Wu et a l, 1997; Brader et a l, 1998; Chaidir et a l, 1999; .
Rocaglamide derivatives ( Fig. 1-2 ) are potent natural insecticides that are comparable with re gard to their insecticidal activity to azadirachtin from the Neem tree Azadirachta indica (e.g. Ewete et a l, 1996; . In addi tion to their insecticidal activity these compounds have also attracted attention due to their cytostatic activity against human cancer cell lines in vitro (Cui et a l, 1997; Wu et a l, 1997) that may be as pronounced as that of the well-known anticancer drug vinblastine . Re cent experiments indicate that the cytostatic activ ity of rocaglamide compounds may also extend to the in vivo level and delay tumor growth in athymic mice (Lee et a l, 1998) . Thus, naturally oc curring rocaglamides or chemical derivatives ob tained from these natural products may possibly be used in future as therapeutical or investiga tional drugs and further studies on their potential antiproliferative activity are required.
0939-5075/99/1200-1075 $ 06.00 © 1999 Verlag der Zeitschrift für Naturforschung, Tübingen • www.znaturforsch.com • D This prompted us to conduct a comparative study on the cytostatic activity of thirteen natu rally occurring rocaglamide derivatives (1-13) ( Fig. 1-2 ) and of an aglain type compound (14) (Fig. 2) . We selected a new series of structurallyrelated compounds and analyzed their effect on the proliferative machinery of fast growing tumor cells in order to identify key elements within the chemical structure conferring the cytotoxic or cy tostatic activity, and possibly to elucidate intracel lular targets of these l//-cyclopenta(b)benzofuran derivatives in malignant cells.
Materials and Methods

Plant material
All examined Aglaia species were collected in Vietnam during February 1998. Flowers and stems of Aglaia duperreana were found near Ho Chi Minh City, whereas the bark and stems of A oligophylla were harvested in Nui Cam, An-Giang Province near the border of Cambodia. Both spe cies were specified by Le Cong Kiet, Dept, of Bot any, University of Ho Chi Minh City, Vietnam. The bark of Aglaia spectabilis was collected on Phu Quoc island, Kien Giang Province and was finally specified by C. Pannell, Dep. of Plant Sci ences, University of Oxford, England. Voucher specimens are on file in the Department of Bot any, Vietnam National University, HCMc, Viet nam.
Isolation of the rocaglamide derivatives
The isolation and structural elucidation of the rocaglamide derivatives with complete data of MS, 'H-and 1 3 C-, 2D-NMR. CD and optical rotation were previously described (Dryer, 1999; Nugroho et al., 1999; Schneider, 1999) .
Chemicals
RPMI 1640-Cell culture medium and supple ments, penicillin and streptomycin were obtained from Gibco-BRL (Eggenstein, Germany). Actinomycin D, cycloheximide, propidium iodide, fetal bovine serum (FBS) and RNAse A were from Sigma (Deisenhofen, Germany). E G M M E (ethyl ene glycol monomethyl ether) was from Merck (Darmstadt, Germany). Methyl-[3 H]-thymidine (specific activity 74 GBq/mmol) and methyl-[3 H]leucine (specific activity 5.44 TBq/mmol) were from Amersham (Braunschweig, Germany) .
Proliferation assays
The rocaglamide derivatives and the aglain de rivative were tested for their antiproliferative ac tivity using the two human monocytic leukemia cell 'lines MONO-MAC-1 and MONO-MAC-6 (Ziegler-Heitbrock et al., 1988) . The cell lines are deposited at the German Collection of Microorga nisms and Cell Cultures (DSMZ, Braunschweig, Germany) .
The cells were grown in plastic flasks (Nunc, Wiesbaden, Germany). All cultures were propa gated using standardized media supplemented with 1 0 -2 0 % heat-inactivated fetal bovine serum and were cultivated at 37 °C in a humidified atmo sphere containing 5% C 0 2. Details are outlined in the D SM Z Catalogue of Human and Animal Cell Lines (Drexler et al., 1999) .
The freeze-dried rocaglamides were dissolved in E G M M E (ethylene glycol monomethyl ether), di luted in RPMI-1640 culture medium and stored frozen at -20 °C. At the final dilution used in the experiments, the E G M M E concentration was 0.1%. For the experiments, exponentially growing cells (viability of >90% as measured by trypan blue exclusion) were harvested, washed and resus pended in fresh medium at a final concentration ranging between 2 and 4 x 105 cells/ml (depending on the cell line). Proliferation assay was carried out as described (Steube et al., 1992) : Aliquots of 90 [.il were seeded out into 96-well flat-bottom cul ture plates (Nunc, Wiesbaden, Germany) . Ten mi croliters with medium, medium with the solvent E G M M E or with different concentrations of the rocaglamide derivatives were added. After a 45 h cultivation period 1 |iCi of [methyl-3 H]-thymidine was given to each well and the cultures were fur ther incubated for 3 h. Cells were harvested on glass fiber filters with a multiple automatic sample harvester, and incorporated radioactivity was de termined in a liquid scintillation counter (1209 Rackbeta. LKB, Freiburg, Germany). Total cell number and viability were determined in a cell counting chamber after staining the cells with try pan blue.
All experiments were carried out in triplicates and repeated three times. As controls, cells were incubated with 0.1% EGM M E in culture medium. To avoid bacterial contamination all experiments were carried out in the presence of 100 IU/ml pen icillin G and 100 [ig/ml streptomycin.
Short term exposure to rocaglamide derivatives:
MONO-MAC-6 cells (density 2 x 105 cells/ml) were plated out in 96-well flat-bottom culture plates. After an over night incubation, the cells were treated with various rocaglamide derivatives for 1 h, followed by a pulsing with 1 [iCi [3 H]thymidine or [3 H]leucine. Radioactive incorporation was determined 2, 4, 6 , 8 hours thereafter.
Cell cycle analysis:
Cells were harvested by centrifugation for 10 min at 400 xg at 4 °C. To the sedimented cells ice-cold 70% ethanol was added drop wise and the samples were fixed in ethanol overnight at 4 °C. After washing with PBS, 1 x 106 cells were incu bated for 15 min. at 37 °C with RNAse (1 ml of 100 j-ig/ml RNAse A). After two more washing steps, cells were resuspended in 500 ^1 PBS. Propidium iodide was added to a final concentration of 20 ng/ml. After 10 min the DNA content of at least 1 0 . 0 0 0 cells was determined by flow cyto metry on a FACScan (Becton Dickinson, Heidel berg, Germany).
Results and Discussion
Thirteen naturally occurring l//-cyclopenta[-b]benzofuran lignans of the rocaglamide type (1 -13) ( Fig. 1-2 ) as well as a naturally occurring ag lain congener (14) (Fig. 2 ) that is structurally closely related to the rocaglamide derivative (13) (Fig. 2) were studied for their antiproliferative ef fect on the human monocytic leukemia cell line MONO-MAC-6 . This cell line is a well established and characterized model system in hematology and immunology (Ziegler-Heitbrock et al., 1988; Ziegler-Heitbrock et al., 1994) and we have used it in previous studies Eder et al., 1998; Steube et al., 1998) . Therefore we were able to directly discuss and compare our new results with those reported recently .
The rocaglamide congeners were selected for these experiments based on structural considera- tions which allow independent determination of the activity modulating effects of different substit uents present at positions 1, 2, 6 , 7, 8 b, 3' or 4' of the basic rocaglamide skeleton ( Fig. 1-2 ). Whereas most rocaglamide derivatives except compounds (6) and (7) were found to clearly in hibit [3 H]thymidine incorporation of MONO-M A C-6 cells, there were nevertheless marked dif ferences in the degree of antiproliferative activity that could be related to distinct structural features of the various compounds (Table I) . Didesmethylrocaglamide (1) and methylrocaglate (2) (Fig. 1) , are the most active rocaglamide congeners en countered in this study, exhibiting IC5 0 values of 0.013 and 0.016 jiM , respectively. With regard to their growth inhibitory activity they are in the same order of magnitude as the well-known anti cancer drug vinblastine sulfate (IC5 0 0.009 ^im) which we have analyzed recently in the same sys tem . Comparison of the IC5 0 values and of the structures of compounds (1 ) and (2 ) indicated that the amide substituent as present in (1 ) can be replaced by a methyl ester group like in (2 ) with no apparent loss of activity. In contrast, if C-2 was unsubstituted as in rocaglaol (3) (Fig. 1 ) the antiproliferative activity of the latter was decreased at least by a factor of four compared to the former derivatives (1) and (2) ( Table I ). This is in congruence with an earlier re port on antiproliferative effects of rocaglamide congeners (Lee et al., 1998) . A similar decrease in the antiproliferative activity as from (2) to (3) was observed from (8) to (9). In both weaker com pounds (3) and (9) the polar ester substituent at position C-2 is replaced by a hydrogen, again em phasizing the importance of a polar residue at C-2. Addition of a methylenedioxy group to the ro caglamide skeleton was found to influence activity of the resulting derivatives in a position specific manner. Compound (11) (Fig. 2) that differs from methylrocaglate (2 ) by a methylenedioxy group linked to C-6 and C-7 of ring A exhibited an IC5 0 value of 0.045 |iM compared to the IC 5 0 of 0.016 (.im for the parent compound (2) ( Table I) . Interest ingly, compound (8 ) (4'-demethoxy-3',4'-methylenedioxy-methylrocaglate) with an IC5 0 value 0 . 0 2 0 [xM that differs from methylrocaglate (2) by presence of a methylenedioxy group at positions C-3' and C-4' of ring B is nearly as active as the parent compound (2) ( Table I) .
The influence of the substitution pattern at ring B on the cytostatic properties of rocaglamide de rivatives is strictly documented by the low and missing proliferative activity of compounds (5) and (12); both congeners carry a methoxy group at C-3' (instead of -H or methylenedioxy).
To summarize, the comparison of the IC5 0 val ues of (3, 5, 9, 12) indicates that both, a methoxy group in ring B and an unpolar substituent at C-2 have negative influence on the antiproliferative activity of rocaglamide derivatives.
The most dramatic structure activity relation as revealed in this study, however, was detected by analyzing compounds (6) and (7) (Fig. 1) were both devoid of antiproliferative activity even when tested at a concentration of 2.0 [ im (Table I) . Both rocaglamide congeners are characterized by an unusual O C H 3 substituent at C-8b whereas the majority of naturally occurring rocaglamide type compounds ( Fig. 1-2 ) features a hydroxyl group at this position. Presence of a O H rather than of a OCH3 substituent at C-8b is therefore essential for the antiproliferative activity of rocaglamide type compounds. Interestingly, l//-cyclopenta(-b)benzofuran type compounds with a methoxy group at C-8b, e.g. (6) and (7) were previously shown to lack also insecticidal activity, whereas their corresponding demethyl parent compounds (2) and (3) are strong natural insecticides . It is therefore conceivable to assume that the intracellular target(s) of rocaglamide con geners are similar or identical both in insects and in human cancer cells. Aglain derivatives such as compound (14) (Fig. 2 ) that often cooccur with structurally related rocaglamide type compounds in Aglaia species (Dumontet et al, 1996; differ from the latter by the nature of the heterocycle (bridged benzopyran vs. benzofuran) and usually by a larger and more spacious amide substituent than encountered with rocaglamide derivatives. In a previous study we reported that aglain type com pounds show no antiproliferative activity and assumed this to be due to the different heterocycles present in both types of compounds, even though a negative influence of the large amide group on the biological activity of aglains could not be ruled out at that time. With the structurally closely related rocaglamide deriva tive (13) (Fig. 2) and the aglain congener (14) now being available for comparative biological studies it could be unequivocally proven for the first time that the loss of antiproliferative activity associated with aglain type compounds can indeed be attrib uted to the presence of the bridged benzopyran moiety of the aglains vs. the benzofuran system of rocaglamide type compounds.
In a previous communication we had demon strated that rocaglamide derivatives act on MONO-MAC-6 cells by a cytostatic rather than by a cytotoxic mechanism . Since the monocytic leukemia cell line MONO-MAC-6 contains both, diploid and tetraploid cells, an exact cell cycle analysis by flow cyto metry was not possible. To evaluate more precisely the cell cycle distribution we have chosen the near diploid cell line MONO-MAC-1 (Steube et a l, 1997) , which has been established from the same patient as MONO-MAC-6 (Ziegler-Heitbrock et a l, 1988). Thus, flow cytometry was carried out with MONO-MAC-1 cells, in presence of the most active compound, didesmethylrocaglamide (1) for a time period of up to 96 h and compared to con trols (Fig. 3) (Table II) .
Prior to the drug treatment about 70% of the cells were in G1-, 20% in S-and 10% in G2/Mphase. The number of cells in G2/M increased con tinuously to 27% during the 96 hours incubation period, in parallel to a decrease of cells in S-phase (Fig. 3) . In addition to the cell cycle analysis we determined cell viability and [3H]thymidine incor poration. The control culture steadily increased its cell number and [3H]thymidine incorporation while the amount of viable cells in the didesmethylrocaglamide-treated culture remained constant (or slightly decreased), and an almost complete stop of [3H]thymidine incorporation was observed (Table II) . These data, together with the fact that we did not detect any significant increase of cells F. I. benzofurans Alter Cell Cycle Distribution in MONO-MAC-6 Cells Control 0.050 Mg/ml didesmethylrocaglamide (1) Fig. 3 . MONO-MAC-1 cells (starting conc. of 0.3 x 106 cells/ml) were incubated with or without 0.050 |ig/ml dides methylrocaglamide (1). A t different time periods (24h, 48h, 72h, 96h) cell cycle analysis was performed as described in Materials and Methods. Shown is the diagram after 96h incubation without (left) and with the rocaglamide derivative (right). Percentage of distribution is given in Table II . in M-phase on Giemsa-or DAPI-stained slides un der the light microscopy (not shown), strongly sug gest that at least a substantial proportion of the MONO-MAC-1 cells were arrested in G2, while another portion remained in G1/G0 phase. Thus, our data differ to a certain degree to those of a recent study (Lee et a l, 1998) that claimed a transient arrest of the cells in the G1/G0 phases of the cell cycle. In contrast to our system Lee et al. (1998) have used a lung cancer cell line (Lul) which seems not to be further certified or charac terized, since the cells are not published and are not available from an international recognized cell bank. They carried out flow cytometry at seven time points, but only 24 hours after start a signifi cant difference between control and drug treated cultures was observed. It is not discussed why the reported G1/G0 arrest is only transient, although the total cell number remained constant through out the whole 72 hours cultivation time. The MONO-MAC-1 cells we used grow as suspension culture whereas lung cells grow adherent and must be trypsinized prior to flow cytometry. It is pos sible that drug-treated lung-cells are less resistant to the trypsin-treatment than the control cells and only an unrepresentative fraction of the culture was analyzed.
In the same study the authors claimed that ro caglamide derivatives act on Lul cells primarily by selective inhibition of protein synthesis rather than by inhibition of nucleic acid synthesis (Lee et a l, 1998) . They reported further that short term expo sure (2-3h) of Lul cells to compound (8) causes severe reduction of protein synthesis (the IC 50 value of (8) was 0.025 (.tg/ml) whereas even signifi cantly higher concentrations of (8) (up to 1.0 [.ig/ ml) failed to reduce DNA synthesis under similar experimental conditions (Lee et al, 1998) .
We have selected 6 rocaglamide derivatives in cluding also compound (8) (4'-demethoxy-3\4'-Compounds (0.100 M g/m l) Fig. 4 . MONO-MAC-6 cells were plated out in 96-well culture plates and incubated overnight. Followed by addition of rocaglamide derivatives at a final concentration of 0.100 (xg/ml. After 1 h incubation 'H-thymidine was added. After an additional 2 h cells were harvested and incorporation of 3H-thymidine was measured. Results are expressed as% incorporation relative to control cultures. methylenedioxy-methylrocaglate) and investi gated their effect on DNA synthesis by measuring [3H]thymidine incorporation for only 3 h (Fig. 4) . Five congeners including compound (8) were able to significantly reduce DNA-synthesis, albeit higher concentrations were needed than in the long-term experiments leading to the IC50 values. Further time-course experiments measuring [3H]thymidine incorporation after 4, 24, and 48 h in this and our previous study unequivocally showed that DNA-synthe sis is indeed affected by more than 20 different rocaglamide derivatives. Studies carried out earlier using various human leukemia cell lines revealed also a dose dependent inhibition of RNA-synthesis (Steube et al., unpublished results) .
Didesmethylrocaglamide (1) being the most active compound detected in this study, reduced DNA and protein synthesis roughly by 50% at concentrations of 0.050 -0.100 [.ig/ml and com pares thus favorably to well-known inhibitors of DNA or protein synthesis such as actinomycin D ( Fig. 4) or cycloheximide (Fig. 5 ) which were used as positive controls. However, our experimental design could not distinguish whether inhibition of D N A or protein synthesis are direct or indirect effects of the com pounds investigated.
Antiproliferative natural compounds exert their biological effects on various intracellular targets. For example, vinblastine inhibits tubulin polymer ization, cytochalasine actin polymerization, whereas actinomycin D, mitomycin and anthracyclines act on DN A replication. Cycloheximide and amanitin inhibit protein biosynthesis via the ribo somal machinery and RNA polymerase II, respec tively. Other natural products interfere with the signal transduction pathway by inhibition of pro tein kinases or phosphatases (staurosporines, calyculines, genistein, herbimycine and many others). And, many if not all applications of these drugs finally results in an inhibition of cell proliferation depending on the concentration used in the indivi dual experiments. Thus a large number of possible targets may exist and a thorough study in isolated cell fractions or cell-free systems should be per formed before a specific mode of action can be suggested for the l//-cyclopenta[b]benzofuran lignans.
Taken together, rocaglamide type compounds have proven to be inhibitors of cellular prolifera tion in a cytostatic, rather than a cytotoxic manner. These substances are promising candidates for fu ture work aiming to improve their biological activ ity by site directed chemical modification thus opening a possible application for rocaglamides as tools in cancer biology.
